Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2483 |
Dacomitinib
达克替尼,PF-299804,PF-00299804,PF299 |
Apoptosis; EGFR | Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Dacomitinib (PF299) 是一种不可逆的特异性ERBB 家族抑制剂,作用于EGFR、ERBB2和ERBB4的IC50分别为 6 nM、45.7 nM 和 73.7 nM。 | |||
T19965 |
Dacomitinib hydrate
PF 299804,:达克替尼一水合物,PF00299804,PF 00299804,PF-00299804,PF299804,PF-299804 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Dacomitinib hydrate (PF 299804) 是泛表皮生长因子受体家族酪氨酸激酶的高选择性第二代小分子抑制剂。 Dacomitinib 特异性且不可逆地结合并抑制人 EGFR 亚型,从而抑制表达 EGFR 的肿瘤细胞的增殖和诱导细胞凋亡。 | |||
T23950 |
Dacomitinib metabolite M2
Dacomitinib cysteine conjugate,UNII-SOA52D3NLL |
||
Dacomitinib metabolite M2 is also known as Dacomitinib cysteine conjugate. Dacomitinib inhibits both the wild-type (WT) EGFR and EGFR T790M. | |||
T67152 |
Dacomitinib Intermediate 2
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin-4-amine |
Others | Others |
Dacomitinib Intermediate 2 (N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin-4-amine) 具有抗癌活性,可用于研究肺癌。 |